New drug duo aims to shrink tumors before colon cancer surgery
NCT ID NCT05706779
Summary
This study is testing whether giving two targeted cancer drugs—encorafenib and cetuximab—before surgery can shrink tumors in patients with a specific genetic mutation (BRAF V600E) in their localized colon or upper rectal cancer. The goal is to see if this 'neoadjuvant' treatment leads to significant tumor regression. The trial aims to enroll 30 eligible patients to assess this approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu - Hôpital Européen Georges Pompidou
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.